Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug

Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by insufficient parathyroid hormone (PTH) levels, leading to hypocalcemia and hyperphosphatemia. Affecting approximately 70 000-90 000 individuals in the United States, HypoPT can arise from genetic mutations or, most commonly, as a result of surgical removal of the parathyroid glands. Traditional treatments involve calcium and vitamin D supplementation, which can pose long-term risks such as renal complications. On 9 August 2024, the U.S. Food and Drug Administration (FDA) approved Palopegteriparatide (Yorvipath, Ascendis, Denmark), a synthetic long-acting PTH analog, for subcutaneous use in adult patients with chronic HypoPT. Palopegteriparatide is designed as a pro-drug that undergoes auto-cleavage, offering sustained release and prolonged systemic exposure to recombinant PTH (1-34). Clinical trials have demonstrated its ability to maintain normocalcemia with minimal need for supplemental calcium or vitamin D. The treatment also showed a favorable safety profile, with mild transient side effects and no significant toxicity. Unlike standard-of-care therapies, Palopegteriparatide maintains balanced calcium-phosphate levels with less renal strain, making it a particularly promising option for patients with compromised kidney function. Although concerns remain regarding long-term safety, its FDA approval and orphan drug designation underscore its importance in addressing the unmet therapeutic needs of HypoPT. Continued investigation is warranted to optimize patient outcomes and further define its risk-benefit profile. This approval marks a critical milestone in endocrine therapeutics and offers renewed hope for patients struggling with the burdens of chronic HypoPT.